Home・Listă Acțiuni・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Închisă

SectorSănătate

19.11 1.16

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

18.8

Maxim

19.34

Indicatori cheie
By Trading Economics
Venit	-24M -54M
Vânzări	-2.5M 305M
EPS	-0.15
Marjă de profit	-17.851
Angajați	3,100
EBITDA	-24M -32M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+175.38% upside

Dividende
By Acuity
Următoarele câștiguri	11 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1B 3.7B
Deschiderea anterioară	17.95
Închiderea anterioară	19.11

Sentimentul știrilor

By Acuity

100%

320 / 340 Clasament în Healthcare

Legend Biotech Corp ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 iul. 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 iul. 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 iul. 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 iul. 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 iul. 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 iul. 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 iul. 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 iul. 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 iul. 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Comparație

Modificare preț

Legend Biotech Corp ADR Așteptări

Obiectiv de preț

By TipRanks

175.38% sus

Prognoză pe 12 luni

Medie 52.35 USD 175.38%

Maxim 80 USD

Minim 28 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLegend Biotech Corp ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Legend Biotech Corp ADR - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.